Initiator Pharma A/S (STO:INIT)

Sweden flag Sweden · Delayed Price · Currency is SEK
3.270
+0.050 (1.55%)
Apr 10, 2026, 5:22 PM CET
Market Cap220.42M -40.5%
Revenue (ttm)n/a
Net Income-19.83M
EPS-0.32
Shares Out68.45M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume72,872
Average Volume54,493
Open3.200
Previous Close3.220
Day's Range3.150 - 3.270
52-Week Range2.560 - 6.900
Beta0.07
RSI55.74
Earnings DateMay 8, 2026

About Initiator Pharma

Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor, which completed phase IIb clinical trial primarily targeting the dopamine system for treatment resistant organic erectile dysfunction, as well as completed phase I to treat neuropathic pain; and IP2018, a monoamine reuptake inhibitor which completed Phase IIa for the treatment of psychogenic erectile dysfunction. The ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 1
Stock Exchange Nasdaq Stockholm
Ticker Symbol INIT
Full Company Profile

Financial Performance

Financial numbers in DKK Financial Statements